Treatment of symptoms of menopause remains a challenge for many health care practitioners. In an effort to facilitate this process, the Endocrine Society convened an international Task Force of menopause experts to review the relevant clinical evidence and formulate practical recommendations for relieving the most common menopausal symptoms. The result is a comprehensive evidence-based guideline, which emphasizes an individualized approach to alleviate bothersome vasomotor symptoms and those related to postmenopausal changes of the vagina and urinary tract. Therapies including estrogen, either alone or in combination with progestogen or bazedoxifene, tibolone, antidepressants, gabapentin, as well as complementary approaches are discussed. In this commentary, the chairs of the Task Force highlight the organization and content of the guideline and the processes involved in its development.
On 7 October, of this year, the Endocrine Society published online its first clinical practice guideline for treatment of symptoms of the menopause. 1 This guideline builds upon our highly successful 2010 Scientific Statement on Postmenopausal Hormone Therapy. 2 As an international society with more than 18,000 members from over 120 countries, our goal in creating this guideline was to be truly global in our approach, acknowledging differences in the populations we serve, our practice patterns, and the prescription therapies available. Our Task Force consisted of six expert menopause physicians from Australia, Europe, the UK, and the U.S. The document was reviewed with feedback provided by the Endocrine Society Guideline Committee, Endocrine Society Clinical Practice Committee, numerous international societies, Endocrine Society members, and the Endocrine Society Council. We think the guideline accomplished our goal to develop a document with global applicability.
After careful consideration, we elected to focus our recommendations on treatment of symptoms of menopause rather than elaborate on important midlife preventive strategies. Among menopause symptoms, we primarily addressed vasomotor symptoms (VMS) and genitourinary syndrome of menopause (GSM). From a treatment perspective, we incorporated both hormonal and nonhormonal prescription therapies as well as over-the-counter remedies and complementary approaches. Our guideline recommendations regarding menopausal hormone therapy (MHT) were largely based on the recent re-analyses of data appearing after initial publication of the Women's Health Initiative (WHI) Study in 2002. 3 Notably, the initial reports of the WHI hormone therapy trial findings resulted in a substantial drop in the use of MHT in many countries including the U.S. 4 In the ensuing dozen years, our knowledge regarding identification of suitable candidates for MHT, dosing options, routes of administration, and benefit/risk ratios has grown considerably. We now are confident that we are better equipped to identify women for whom the benefits of MHT substantially outweigh the risks.
A key component of our guideline involves baseline risk assessment for women considering treatment of menopausal symptoms. In general, the benefit of MHT would exceed risk in symptomatic women aged 50-59 or less than 10 years after onset of menopause who have no contraindications to MHT and acceptable levels of risk for both breast cancer and cardiovascular disease. Several estrogen or estrogen plus progestogen approaches are recommended as well as tibolone, and under appropriate circumstances, the tissue selective estrogen complex (conjugated equine estrogen plus bazedoxifene). We discuss contraindications to all prescription therapies and conditions for which therapies should be approached with caution. Because of concerns with potential increased risks of MHT, we encourage baseline evaluation of cardiovascular risks for myocardial infarction, stroke, and venous thromboembolic disease as well as recommendations for assessing breast cancer risk. Again, recognizing the spectrum of preferred instruments throughout the world and the limits of evidence justifying this recommendation, we allow wide berth in selecting the specific risk determination method, but nevertheless emphasize the anticipated value of going through the exercise prior to recommending a treatment regimen.
For women with moderate or severe VMS, the Guideline also recommends effective nonhormonal therapies including SSRI/SNRI and gabapentinoid agents. These are less effective than MHT, but reduce symptoms significantly. For women without moderate to severe VMS, GSM is best treated with local vaginal estrogen therapy. The selective estrogen receptor modulators (SERM), ospemiphene, is a newer agent to treat dyspareunia associated with vaginal atrophy and can be considered in women without contraindications.
Finally, and perhaps most importantly, we emphasize an individualized clinical approach. We take into account a woman's symptom complex, with the goal of understanding how bothered is she by her symptoms and what impact they have on her quality of life. We recognize that a woman's personal preferences are key factors when formulating a plan for symptom relief, particularly as an ever-increasing spectrum of treatment options is available. Knowledge of overall health status, with a clear picture of lifestyle, concurrent medical concerns, and possible psychological symptoms helps to tailor a personalized approach to managing each woman's menopausal symptoms.
In order to facilitate use of the guideline, we have mapped out five distinct sections. The first includes definitions and diagnosis of menopause. The second acknowledges health considerations for all midlife women, regardless of menopausal symptoms. The third section focuses on options for women with moderate to severe VMS who are interested and lack contraindications for MHT. The fourth section is geared toward equally symptomatic women who, due to personal preference or medical contraindications, are better suited to nonhormonal prescriptions and complementary therapies. The fifth and final section is devoted to a discussion of treatment options for GSM, a symptom complex for which many women still suffer in silence either unaware of therapeutic options or reluctant to disclose concerns to their clinicians.
In Section 1, consistent with the Stages of Reproductive Aging þ10 consensus, we rely primarily on menstrual cycle patterns to establish the diagnosis of menopause. 5 We explain that this guideline focuses on treatment of symptoms of the late perimenopause or postmenopause. We do not provide a detailed discussion of treatment options for symptoms and concerns unique to the menopause transition nor do we elaborate on issues specific to primary ovarian insufficiency.
As previously mentioned, Section 2 acknowledges important lifestyle maneuvers and preventive strategies to optimize the postmenopausal phase. We recognize the menopause transition as a portal to the second half of life, and as such, think it important to highlight these vital measures.
Section 3 makes up the bulk of the guideline and dominates the number of recommendation statements. We carefully discuss risks and benefits of MHT, with an emphasis on absolute risk to facilitate patient counseling, recommendations for assessing individual risk, tailoring hormone therapy, monitoring during hormone therapy, and stopping considerations. We also include discussions of combination therapy with conjugated estrogen and bazedoxifene, as well as tibolone, although these agents are not available in all countries.
Nonhormonal strategies for treating VMS are highlighted in Section 4. In addition to discussing prescription therapies such as commonly used antidepressants, gabapentin, and clonidine, this section elaborates upon available evidence assessing popular over-the-counter remedies and lifestyle approaches such as yoga, hypnosis, and cognitive therapies. We elaborate on the challenges in interpreting some of this data considering the very powerful placebo effect demonstrated in randomized placebo-controlled clinical trials evaluating agents for VMS relief.
Section 5, treatment of GSM, evolved at the same time this new nomenclature was introduced. 6 The Task Force decided that the expansion of this symptom complex to GSM-including vulvovaginal atrophy along with urinary symptoms-more accurately reflected patient experiences. We incorporate a unique analysis of vaginal therapies according to dose and emphasize the anticipated safety and efficacy of low-dose local therapies.
The final contribution of our guideline is a discussion of the research agenda moving forward.
The exercise of compiling the available evidence to support our recommendations repeatedly highlighted the scientific gaps and challenges ahead. A fuller understanding of the mechanism of VMS remains to be elucidated. Comparative risks and benefits of different MHT preparations, doses, and routes of administration would ideally require head to head clinical trials of sufficient duration in relatively younger recently postmenopausal symptomatic women. We acknowledge that these are difficult to conduct and finance, however. Establishing safety of therapeutic choices for women during the menopause transition, as well as elucidating the optimal approach for symptom management and prevention in women with early menopause remains prominent among research frontiers.
By convention, the Endocrine Society Guidelines are formulated, formatted, and presented in a consistent manner. The methods used in the development of this guideline are fully disclosed. The printed document starts with a summary of the 34 guideline recommendation statements; each recommendation is graded for level of evidence. In subsequent sections, the recommendation statements are followed by a discussion of supporting evidence. To those who have not been involved in generation of a guideline, the checks and balances provided by the Endocrine Society are impressive. The topic of the guideline is first established by Endocrine's Clinical Guideline Committee. This group also vets and accepts potential Task Force members. During the writing process, numerous external reviewers were tapped to share expertise and critique our recommendations. Once our writing was complete, the guideline was turned over to two medical writers who homogenized our group syntax and struggled mightily to correctly order 368 references. The document was then approved by the same Clinical Guidelines Committee as well as the Clinical Practice Committee of the Endocrine Society. All comments and suggestions by those groups were reviewed and written responses were provided. The guideline draft was then made available to the full membership of the Endocrine Society with a similar review process. Following that feedback, the guideline was presented to co-sponsoring societies (listed at the conclusion of the guideline), such as the British Menopause Society, whose designated leadership provided helpful suggestions which improved our final product. Following review by the Council of The Endocrine Society, the last step was submission for review by the editors and external reviewers of the Journal of Clinical Endocrinology and Metabolism. They provided added oversight and suggestions including a request for incorporating compliance with parameters of the AGREEII assessment tool.
We are grateful to the British Menopause Society for endorsing our guideline and hope that this brief introduction entices your members to review and consider incorporating these recommendations into practice. 
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